Asia Green Biotechnology Corp. Stock

Equities

ASIA

CA04522C1041

Pharmaceuticals

Market Closed - Canadian Securities Exchange 01:34:38 2024-02-06 pm EST 5-day change 1st Jan Change
0.015 CAD +50.00% Intraday chart for Asia Green Biotechnology Corp. -.--% +50.00%
Sales 2021 - Sales 2022 - Capitalization 544K 745K
Net income 2021 - 0 Net income 2022 - 0 EV / Sales 2021 -
Net Debt 2021 82.73K 113K Net Debt 2022 213K 291K EV / Sales 2022 -
P/E ratio 2021
-2.49 x
P/E ratio 2022
-2.73 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 45.03%
More Fundamentals * Assessed data
Dynamic Chart
Asia Green Biotechnology Corp. Announces Discontinuation of Any Further Activities in Asia, in Particular, in Cambodia and Thailand CI
Burton Growers Ltd. & Green Sight Agri-Holdings Inc. entered into a non-binding letter of intent to acquire Asia Green Biotechnology Corp. for CAD 4 million in a reverse merger transaction. CI
Asia Green Biotechnology Corp. announced that it expects to receive CAD 1.5 million in funding CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Asia Green Biotechnology Corp. Announces Passing of Johannes Kingma, Director CI
Asia Green Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Asia Green Biotechnology Corp. Partners with Pathway Rx Inc. to Pursue Clinical Trials Activities in the Development of A Migraine Treatment Utilizing Cannabis and Hemp Extracts Controlled by Pathway Inc CI
Asia Green Biotechnology Corp. Announces Resignation of Daryl Hudson as Director CI
Asia Green Biotechnology Corp. Auditor Raises 'Going Concern' Doubt CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Asia Green Biotechnology Corp. Proceeds to Next Phase of Migraine Clinical Study CI
Asia Green Biotechnology Corp. Proceeding to Next Phase of Migraine Clinical Study; Extending Financing Arrangement MT
Asia Green Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
More news
1 day+50.00%
3 months+50.00%
6 months+50.00%
Current year+50.00%
More quotes
Current year
0.00
Extreme 0
0.08
1 year
0.00
Extreme 0
0.08
3 years
0.00
Extreme 0
0.12
5 years
0.00
Extreme 0
0.30
10 years
0.00
Extreme 0
0.79
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 18-01-08
Director of Finance/CFO 53 18-01-08
Members of the board TitleAgeSince
Chief Executive Officer 67 18-01-08
Director of Finance/CFO 53 18-01-08
Director/Board Member - 21-01-21
More insiders
Asia Green Biotechnology Corp. is a Canada-based early-stage international agro-technology company. The Company is focused on the development, evaluation, testing, application and, ultimately, supply to the market of organic hybridization technology and certain products derived from that technology (the Technology). The Company is engaged in planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities under the terms of the license agreement with InPlanta Biotechnology Inc. (InPlanta) and the evaluation and development of medicinal and related cannabinoid extracts under the terms of license agreements with Swysh Inc. (Swysh), and Pathway Rx Corp (Pathway Rx). It is in the process of establishing and implementing research and development programs in Cambodia and Thailand and continues to evaluate the potential to expand its business operations to other countries in the region.
More about the company